The Effects of Mesenchymal Stem Cell Secretome in Rheumatoid Arthritis Patients
Launched by UNIVERSITAS SEBELAS MARET · Jun 26, 2023
Trial Information
Current as of May 13, 2025
Completed
Keywords
ClinConnect Summary
This research is experimental. The research subjects were 30 rheumatoid arthritis patients. The control group received a placebo, and the treatment group received mesenchymal stem cell secretome on the 1st, 2nd, 3rd, 4th, 5th, 6th, 7th, 14th, 21st, and 28th. The data collected were erythroblastic acidity, hsCRP, interlukin 6, DAS-28, and assessment of drug side effects before and after therapy. Statistical test with paired difference test with p\<0.05
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Rheumatoid Arthritis Patients
- Exclusion Criteria:
- • Pregnancy
About Universitas Sebelas Maret
Universitas Sebelas Maret (UNS) is a prominent educational institution in Indonesia, committed to advancing research and innovation in various fields, including health sciences. With a strong emphasis on clinical research, UNS strives to enhance medical knowledge and improve patient care through rigorous scientific investigation. The university collaborates with multiple stakeholders, including healthcare providers and governmental bodies, to conduct clinical trials that adhere to ethical standards and contribute to global health advancements. UNS is dedicated to fostering a culture of excellence in research, training future healthcare professionals, and addressing pressing health challenges in the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Surakarta, Middle Java, Indonesia
Patients applied
Trial Officials
Nurhasan Agung Prabowo, MD
Principal Investigator
Universitas Sebelas Maret
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported